NCT05984615已完成不适用
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,961
- 试验地点
- 1
- 主要终点
- Race
研究概览
简要总结
This was a retrospective real-world evidence cohort study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Race
时间窗: Baseline
Eastern Cooperative Oncology Group performance status (ECOG PS)
时间窗: Baseline
The ECOG scale consists of 4 grades (from 0 to 4) where 0 implies fully active, and 4 implies completely disabled.
Number of metastatic sites
时间窗: Baseline
Mean age
时间窗: Baseline
Number of male patients
时间窗: Baseline
Mean Charlson comorbidity index (CCI) score
时间窗: Baseline
Comorbidity was categorized into three grades: mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores ≥5.
Number of patients with study-related biomarkers
时间窗: Baseline
Study-related biomarkers included BRAF and PD1/PDL1 test dates and results.
次要结局
- Progression-free survival (PFS)(6 months and 1, 1.5, and 2 years)
- Overall survival (OS)(6 months and 1, 1.5, and 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian FederationChronic Hepatitis CNCT03053180AbbVie60
Unknown
不适用
T-DM1 in HER2-positive Metastatic/Relapsed Breast CancerBreast CancerNCT04202328Samsung Medical Center1,000
已完成
不适用
Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaGastric or Gastroesophageal Junction AdenocarcinomaNCT04192734Hallym University Medical Center1,063
已完成
不适用
Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With ChemotherapyMetastatic Breast CancerNCT06619704Novartis Pharmaceuticals194
已完成
不适用
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast CancerBreast CancerNCT06075758Novartis Pharmaceuticals175